Final answer:
SGLT2 inhibitors are a class of diabetic drugs that can cause euglycemic DKA. Unlike sulfonylureas, which increase insulin secretion and can cause hypoglycemia, SGLT2 inhibitors reduce glucose reabsorption in the kidneys. Pharmacogenetics can tailor diabetes treatment to individual genetic profiles.
Step-by-step explanation:
The diabetic drug that can cause euglycemic Diabetic Ketoacidosis (DKA) is an SGLT2 inhibitor. While drugs like sulfonylureas, such as gliclazide, stimulate beta cells to secrete insulin and can cause hypoglycemia, SGLT2 inhibitors work by a different mechanism. They prevent glucose reabsorption in the kidneys, which can lead to normal or near-normal blood sugar levels even during ketoacidosis. This condition is known as euglycemic DKA because blood sugar levels are not markedly elevated as is typical in DKA, making the condition harder to detect. It should be noted that SGLT2 inhibitors are more commonly associated with euglycemic DKA in type 1 diabetes rather than type 2. In the backdrop of diabetes treatments and personal genetic makeup, pharmacogenetics emerges as a way to tailor treatments for individuals, and this field represents a new frontier in medicine.